All posts by imreal

Morphisec Appoints Eric Dougherty as Chief Revenue Officer


Morphisec

Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.

Morphisec, the leader in Moving Target Defense, today announced it has appointed Eric Dougherty to Chief Revenue Officer (CRO). In this role, Dougherty will lead all customer acquisition, expansion and retention efforts for the company as it accelerates its growth in global markets. Morphisec has doubled the global install base of its Unified Threat Prevention platform in just over eight months to more than four million endpoints as demand skyrockets for its advanced threat protection as the ideal companion to Microsoft’s built-in Windows Defender Antivirus (AV) in more efficient enterprise security stacks.

“We’re excited to have Eric join our team as a paradigm shift is occurring in the cybersecurity market where enterprises are moving to a prevention-first model against advanced attacks as the limitations and burdens of EDR solutions becomes more apparent,” said Ronen Yehoshua, Morphisec’s CEO. “Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.”

Dougherty has over two decades of experience working with growth companies in the cybersecurity, data protection, and enterprise infrastructure markets. He most recently served as VP of Americas Sales for EnterpriseDB. Prior to that, he was the SVP of worldwide sales for Unitrends. Within that role, Dougherty built the sales and channel strategy for Unitrends that resulted in a 400% growth and hitting a $100M run rate in less than four years. During his previous stints at Rapid7 and Acronis, Dougherty built go-to-market channel strategies and sales teams that led to partner expansion, customer wins, and sales growth. Dougherty also spent more than six years at Axis Communications, where his sales success as General Manager for the Americas contributed to a successful IPO in 2000.

“As enterprises move to Windows 10 they are realizing the time has come to step away from legacy antivirus tools, as well as the cost and time burden of EDR solutions,” added Dougherty. “Morphisec is reaping the benefits of the enterprise adoption of Windows Defender AV as organizations of all sizes divest themselves from redundant tools and reallocate budgets to their biggest current need — advanced threat protection. I look forward to expanding Morphisec’s sales team to meet this global demand and assisting our customers with implementing preventative endpoint security within a simpler operational environment that improves their ROI.”

About Morphisec

Morphisec delivers an entirely new level of innovation with its Moving Target Defense-powered Unified Threat Prevention Platform – placing defenders in a prevent-first posture against the most advanced threats to the enterprise, including APTs, zero-days, ransomware, evasive fileless attacks and web-borne exploits. Morphisec provides a crucial, small-footprint memory-defense layer that easily deploys into a company’s existing security infrastructure to form a simple, highly effective, cost-efficient prevention stack that is truly disruptive to today’s existing cybersecurity model.

Share article on social media or email:

VISTAAR Announces Addition of “ADVISORY Playbooks” to it’s Regulatory & Clinical Intelligence Platform


VISTAAR-Regulatory-Clinical-Intelligence

VISTAAR

Access Regulatory Guidance Documents with One Click

VISTAAR released ADVISORY Playbooks to help small and mid-level companies who need advisory either as a primary strategy or as re-assurance / 2nd opinion to their internal strategies they formed for developing or launching new products or expanding to new countries.

Lot of users when going into new markets, or planning to change their product elements and want to know the impact, introducing new product or to support their R&D teams, have ideas and thoughts but may not have a question clearly framed. VISTAAR while driving initial probing questions, you can give your needs or plans and VISTAAR than by leveraging its AI engine provides you a Regulatory strategy on what is needed, options, country requirements, forms/checklists, what other companies are doing in that scenario, what other products have those situations or parameters and more.

When someone cannot afford a senior consultant or need an initial pathway, these Playbooks can drive that process by significantly reducing the time and cost required compared to analyzing all the documents and information manually.

Try for a month FREE to test it for yourself. VISTAAR’s AI enabled Intelligence helps navigate today’s complex product development and regulatory landscape Better, Faster and Cheaper than any other regulatory and clinical intelligence platform. Visit http://www.vistaar.ai

Share article on social media or email:

Study indicates early infusion of mononuclear cells could aid in recovery from stroke


https://www.prweb.com/

Lead investigator on the study, Sean Savitz, M.D.

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke — caused by a blocked artery — which affects over 13 million people each year, according to the World Health Organization.

The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.

Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. “Having found no clear evidence of harm to the initial 10 patients,” he said, “we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type — bone marrow mononuclear cells (BM MNCs) – dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases.”

BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.

“In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy,” added Dr. Savitz, “MNCs do not require passage in culture, which allows for testing in the early post-stroke time window.”

Each patient in the Savitz team’s study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

“In the light of our findings,” said Dr. Savitz, “we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery.”

“New options to treat Ischemic stroke are desperately needed,” said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient’s own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke.”

The full article, “Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Symphony Post Acute Network Selects Trella Health as Ally in Healthcare Technology Revolution


Symphony Post Acute Network, a premier skilled nursing provider that operates 26 facilities across four states, announced the selection of Trella Health (formerly Excel Health) as its post-acute outcomes data and performance analytics solution.

“I was impressed with the level of insight related to market dynamics and structure that [Trella’s] simple to navigate platform delivers,” said Michael Munter, Chief Operating Officer of Symphony. “We are proud to be a leader in the healthcare technology revolution and welcome the opportunity to partner with innovative firms like Trella as our industry continues to develop, mature, and adapt to the ever-changing healthcare landscape.”

Trella Health CEO Ian Juliano echoed Munter’s sentiment, stating, “We’re thrilled to add Symphony to our growing list of skilled nursing customers. They’re a company that has truly embraced the power of data, from both a clinical and business operations standpoint- and bridging that gap to improve outcomes is the future of healthcare.”

Symphony has been experimenting with using technology to assist with clinically appropriate ways to reduce hospital readmissions, including employing a machine learning platform to assess and score incoming patients, so selecting Trella as an analytics provider was a natural solution. With access to the healthcare industry’s most current and complete data, Trella’s solutions for skilled nursing, home health, and hospice empower customers to transform their marketing and sales efforts, grow their care networks, and compare and improve quality while optimizing costs. To learn more about the Trella Health platform, please contact us at info@trellahealth.com or visit http://www.trellahealth.com and grow your business with confidence.

About Symphony Post Acute Network

Symphony Post Acute Network is one of the most innovative providers of post-acute care in the United States. They are a proud, family-focused organization that takes a proactive approach to delivering quality outcomes for the guests in their care. Symphony is committed to making every one of its locations the Provider of Choice in the community that they serve by demonstrating an unmatched ability to meet patients’ needs and offer them a consistently high level of quality care. Ten of Symphony’s facilities have been accredited by the Joint Commission for ensuring the highest standards in the industry. The four rings in the logo represent the important roles that guests, community, family, and staff play in Symphony’s approach to providing the best possible care.

About Trella Health

Trella Health provides post-acute business development leaders with the most complete picture of care activity in their service areas so they can explore new opportunities for growth. As one of only a few companies in the country deemed ‘Innovators’ under the Center for Medicare and Medicaid Service’s Virtual Research Data Center Program, Trella has access to 100% of Medicare Part A and Part B claims data. Trella analyzes 1.2 billion claims annually and presents relevant insights to nearly 10,000 users so they can build higher-performing care networks, serve more patients, and reduce the cost of care.

Share article on social media or email:

Intrinsic ID and Guardtime Create Blockchain-based Security Architecture for Renewable Energy Trading System Supporting Rotterdam’s ‘Digital Twin’ Initiative


Intrinsic ID

Intrinsic ID

We are thrilled to have worked on this project together and look forward to deepening our relationship with Intrinsic ID. New approaches, such as the combination of Instrinic ID’s PUF technologies and Guardtime’s KSI Blockchain, will become increasingly more important. – Mike Gault, CEO, Guardtime

Intrinsic ID, the world’s leading provider of digital authentication technology for Internet of Things security, and Guardtime, the global leader in enterprise blockchain, today announced the companies have completed their joint work on a blockchain-based security architecture for a renewable energy trading system. This distributed-ledger-based real-time energy marketplace for solar, wind and battery is in support of the city of Rotterdam’s “Digital Twin” initiative.

The companies completed presentation and demonstration of the Phase II Small Business Innovation Research (SBIR) project “Open Energy Network” to the Dutch Ministry of Economic Affairs, BlockLab and Enterprise Agency RVO, which stimulates entrepreneurs in sustainable, innovative and international business.

Rotterdam is creating a “digital twin” for the city, which will act as a platform for a new era of digital city applications. The digital twin is a smart 3D model of Rotterdam that accurately represents the streets, buildings, public spaces and other physical elements of the city. The critical nature of this marketplace demands best-in-class security, including a hardware-based root of trust powered by SRAM PUF – physical unclonable function – complemented by blockchain-based distributed ledger technology.

The project is funded under a contract awarded by the Dutch government and the city of Rotterdam, and managed by BlockLab, a subsidiary of the Port of Rotterdam. BlockLab develops use cases with alliances including engineers, developers and end users, with a focus on energy and logistics.

“We have demonstrated how Intrinsic ID’s SRAM PUF technology and Guardtime’s KSI blockchain technology create synergistically a strong solution for the renewable energy markets,” said Pim Tuyls, chief executive officer of Intrinsic ID. “It is a pleasure to have created a combined solution together with Guardtime for the City of Rotterdam to allow them to optimize energy utilization in a secure manner.”

KSI Blockchaiin is an especially efficient method for issuing and verifying signatures which accelerates the scalability of SRAM PUF.

“We are thrilled to have worked on this project together and look forward to deepening our relationship with Intrinsic ID,” said Mike Gault, chief executive officer of Guardtime. “Traditional technologies such as PKI are completely impractical in a world of 5G networks and edge computing and new approaches, such as the combination of Instrinic ID’s PUF technologies and Guardtime’s KSI Blockchain, will become increasingly more important.”

The project was prompted as an answer to a major challenge the region of Rotterdam faces, the suboptimal utilization of energy capacity. To address this, the Dutch government seeks to transform energy markets from closed and centralized to open and distributed. The metropolitan region of Rotterdam and The Hague have a combined population of 2.2 million, with 1 million homes and 128 thousand companies – including the Port of Rotterdam, the largest port in Europe.

In Phase I of the joint project by Intrinsic ID and Guardtime, a cloud-based demonstrator with connected smart meters was developed, combining the core strengths of the two companies. Intrinsic ID’s BroadKey is a proven software solution for authentication of IoT devices such as smart meters. Authenticating smart meters securely at a hardware level by means of software, identifying every member in the network, brings the necessary level of IoT device security and makes it impossible for unauthorized devices to join. Guardtime’s KSI Blockchain is used to ensure integrity and time of every event in the network – making them verifiable independently, regardless of vendors, distribution networks or service providers.

Phase II of the project goes beyond the proof of concept and is tackling the challenges of scalability and end-to-end security for this multiparty complex ecosystem of energy network. Intrinsic ID has worked on the Firmware-Over-The-Air secure updates of smart meters, allowing millions of smart meters to receive verifiable updates with the latest software and firmware libraries, system policies and network configurations. This enables managing millions of smart meters in a time-efficient and low-cost way by avoiding time-consuming manual efforts.

Intrinsic ID and Guardtime supported an extra security layer to support trustworthy communications. This allows the reading values of smart meters to arrive to a decentralized trading platform reliable and secure, without intermediate networking parties have access to them, and assuring that the smart meter cannot deny the authenticity of the measurements.

About Guardtime

Guardtime is the world’s leading enterprise blockchain company. The company was founded in Estonia in 2007, where it products are used to underpin Estonian digital society, and has since expanded with a presence in the UK, Middle East, Asia and the Americas. Example solutions that the company has built, working with industry partners, include GDPR compliance as service, physical anti-counterfeit, marine insurance data exchange, physical supply chain track and trace, digital content management, software lifecycle management, critical infrastructure protection and health-care interoperability.

About Intrinsic ID

Intrinsic ID is the world’s leading digital authentication company, providing the Internet of Things with hardware-based root-of-trust security via unclonable identities for any IoT-connected device. Based on Intrinsic ID’s patented SRAM PUF technology, the company’s security solutions can be implemented in hardware or software. Intrinsic ID security, which can be deployed at any stage of a product’s lifecycle, is used to validate payment systems, secure connectivity, authenticate sensors, and protect sensitive government and military systems. Intrinsic ID technology has been deployed in more than 150 million devices. Award recognition includes the Cyber Defense Magazine InfoSec Award, the IoT Breakthrough Award, the IoT Security Excellence Award, the Frost & Sullivan Technology Leadership Award and the EU Innovation Radar Prize. Intrinsic ID security has been proven in millions of devices certified by Common Criteria, EMVCo, Visa and multiple governments. Intrinsic ID’s mission: Authenticate EverythingTM. Visit Intrinsic ID online at http://www.Intrinsic-ID.com.

Intrinsic ID, the Intrinsic ID logo, BroadKey and “Authenticate Everything” are trademarks or registered trademarks of Intrinsic ID, B.V., and are protected by trademark laws of the United States and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective companies.

Media Contact for Guardtime

Rachel De Haan

Guardtime Global Media Relations

pr@guardtime.com

Media Contact for Intrinsic ID

Milan G. Lazich, Sr. Director Marketing

[+1] 408-933-9980

press@intrinsic-id.com

Experienced Disability Advocate Alexandria Baland Joins Pond Lehocky Disability


Pond Lehocky Stern Giordano Disability is pleased to announce that it has added Alexandria Baland as a Social Security disability associate with the nationwide advocacy group. Ms. Baland has dedicated most of her career to providing legal assistance to disabled individuals. Her knowledge and experience should be a tremendous asset in helping the group serve those with disabilities.

Before joining Pond Lehocky Disability, Ms. Baland worked as an associate at New Jersey law firm, assisting disabled children and their families with matters including guardianship and special needs trusts. She also frequently spoke to groups for parent of disabled children regarding Social Security disability, special education and other related topics.

She has also served as a staff attorney at a New Jersey non-profit that provides free legal services to indigent clients, handling Social Security, housing and other civil matters. In addition, she has worked as a document review attorney, assisting a large Philadelphia law firm in pharmaceutical injury litigation.

While attending school, Ms. Baland emphasized service to the disabled. She graduated from Syracuse University College of Law’s Disability Law and Public Policy joint degree program, earning her J.D. and a master’s degree in disability studies and receiving recognition for her pro bono work. While there, she worked as a student attorney at the school’s Disability Rights Clinic, assisting the disabled with issues including special education, accessibility and prisoners’ rights. She also served as president of the Disability Law Society.

Ms. Baland earned her bachelor’s degree in political science and Spanish from Temple University, where she was a member of the school’s Division I rowing team. She is fluent in both English and Spanish.

Pond Lehocky Disability was the result of the tremendous growth of the law firm of Pond Lehocky Stern Giordano. After becoming the largest firm of its kind and assisting more than 85,000 Americans in all 50 states and Puerto Rico, the firm’s Social Security disability department became its own advocacy group – Pond Lehocky Stern Giordano Disability. Pond Lehocky Disability has teams of experienced disability attorneys and staff members exclusively dedicated to assisting clients with their SSD and Supplemental Security Income cases throughout all 50 states and Puerto Rico.

Share article on social media or email:

Precision Botanical Launches the Purest CBD Brand Available That is Tested for Over 400 Contaminants Setting New Standards for All CBD Products


https://www.prweb.com/

Precision Botanical is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants.

A new CBD brand that launched today seeks to disrupt the industry with its products’ transparency, purity, label accuracy and superiority. Colorado-based Precision Botanical enters the market as the only “Science First” CBD brand that was created by a team of U.S.-based neuroscientists, chemists and toxicologists. Precision Botanical products come from its own Oregon hemp farm and uses a commercial-level proprietary extraction of hemp oil that’s in the patent process. All products are third-party audited and certified for potency and purity.

Approximately 45% of the top 10 CBD brands’ products contain THC and third-party testing reveals that the top selling products are on average tested for fewer than 20 contaminants. In comparison, Precision Botanical tests all of its source material as well as finished products for more than 400 contaminants. This ensures Precision Botanical products are 99% pure, with accurate concentrations in each product and all are made with pharmaceutical-level precision. All of its products carry Clean Label Project Purity and THC-Free Certification.

Precision Botanical CBD products include its Soothe line. These topicals provide mess-free application and each one easily fits into a daily regimen. They contain functional, natural ingredients and were created for athletes by athletes. The Soothe line features:


  • Soothe Roll-on (MSRP $24.99 for 10 ml)
  • Soothe Salve (MSRP $44.99 for 1 oz)
  • Soothe Salve with Menthol (MSRP $44.99 for 1 oz)

Other product lines offered by Precision Botanical include its Calm, Renew, Alert and Sleep lines:

  • Renew Face Cream (MSRP $44.99 for 1 oz)
  • Renew Eye Cream (MSRP $ 44.99 for 1 oz)
  • Calm Tincture (MSRP $44.99 for 750mg, MSRP $19.99 for 300mg)
  • Calm Capsules (MSRP $44.99 for 30-count; MSRP $7.99 for 4-count)
  • Sleep Capsules (MSRP $54.99 for 60-count)
  • Gummies (MSRP $9.99 for 6 count; MSRP $19.99 for 20-count)
  • Alert Shot (MSRP $7.99 for 2oz)
  • Alert Capsules (MSRP 7.99 for 4-count)

Visit https://precisionbotanical.com/ to purchase all Precision Botanical products or to learn more.

About Precision Botanical

Denver, Colorado-based Precision Botanical is committed to quality, purity and transparency in creating the best CBD products available anywhere. It’s the only “Science First” CBD brand on the market founded by a team of neuroscientists, chemists and toxicologists. It also is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants. All product comes from its 100-acre farm in the U.S. and both source materials and finished products are continually tested for purity and accuracy, providing consumers with the peace of mind they deserve.

Share article on social media or email:

Access Healthcare Appoints Jessica Cooley as Chief Marketing Officer


Jessica Cooley, Chief Marketing Officer, Access Healthcare

Jessica Cooley, CMO, Access Healthcare

The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.

Access Healthcare, one of the largest providers of healthcare revenue cycle management and IT services, today announced that Jessica Cooley has been appointed to the company’s executive leadership team as Chief Marketing Officer. In her new role, Cooley will spearhead the company’s global branding and marketing initiatives enabling the customer-facing sales efforts and building the teams towards executing the company’s strategic vision.

Cooley brings more than 17 years of experience in the healthcare industry and has a track record of generating significant profit, enhancing corporate credibility, and increasing market penetration. Prior to Access Healthcare, she was the Vice President of Strategic Accounts & Implementation for Provista, a Vizient subsidiary. While at Provista, she created and led the organization’s Strategic Accounts business unit, which now operates over $91 million in revenue responsibility. Cooley was instrumental in the ambulatory strategy development and execution as part of Provista’s long term growth plan. Cooley has earned several honors including President’s Circle 2016, Sales Excellence 2010, and Exceeding Excellence for 2003 and 2008.

“We are happy to welcome Jessica to our executive leadership team. Over the last few months, we’ve been focusing on building a strategy for how sales and marketing functions to enable the next phase of company’s growth,” says David Tassoni, President of US Operations of Access Healthcare. “We have been growing exponentially and Jessica’s deep marketing experience and strong business insights will bring significant opportunities for Access Healthcare and our business teams as we continue to move forward.”

“Access Healthcare is one of those brands that is revolutionizing the healthcare industry, and I’m truly excited to be part of this growing company,” says Cooley. “The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.”

Cooley holds a B.S. in Human Development from Texas Tech University and is an active member of organizations such as the Young Men’s Service League, Professional Women in Healthcare, and the National Charity League.

About Access Healthcare

Access Healthcare provides business process outsourcing, applications services, and robotic process automation tools to healthcare providers, payers, and related service providers. The company operates from 19 delivery centers in the US, India and the Philippines, and its 12,000+ staff is committed to delivering revenue cycle excellence by leveraging technology, emerging best practices, and global delivery. Based in Dallas, Access Healthcare supports over 300,000 physicians, serves 80+ specialties, processes over $70 billion of A/R annually, and ascribes medical codes to over 30 million charts annually. To learn more, please visit http://www.accesshealthcare.com.

Share article on social media or email:

HIPAA One Raises Standard of Cybersecurity Controls Exclusively to Subscribers


These new cybersecurity questions elevate the standard of security satisfying the most-stringent security certifications while maintaining HIPAA compliance.

HIPAA One today announced a new set of HIPAA One Security risk analysis questions available exclusively to HIPAA One subscribers. These new questions come ahead of the new 42 CFR Part 2 coverage and updates to the final reporting engine coming later in Q4 2019.

Delivering on the promise of reducing the likelihood of breaches, HIPAA One’s new cybersecurity questions elevate the standard of security satisfying the most-stringent security certifications while maintaining HIPAA compliance.

“When we launched HIPAA One’s software platform, the goal was to simplify and reduce administrative burden in conducting and maintaining a HIPAA SRA by at least 80%,” said Steven Marco, President and CEO of HIPAA One. “Today we see gaps between the SRA and ever-evolving cybersecurity threats facing healthcare. Common-sense dictated leveraging HIPAA’s safeguards to evolve new standards for healthcare and its business associates. Now, subscribers can take advantage of this new functionality without any increase in fees while reducing cybersecurity risk to their organizations.”

New cybersecurity questions and supplied policies and procedures directly address:

•Data Classification and Data Loss Prevention 164.312(b)

•Systems Development Lifecycle (for business associates and in-house software development) 164.308(a)(8)

•Mobile Device Management & Mandatory Policy for BYOD (Bring your own Devices) 164.308(a)(5)(ii)(D), 164.310(d)(2)(ii), 164.312(a)(2)(iv)

•Change Management process as part of security evaluations 164.308(a)(8)

•Replacing weak passwords with passphrases or Multi-Factor Authentication (MFA) 164.312(d)

•Using the recently upgraded (and included) Vendor Management Solution (VMS) app, optionally requiring Business Associates provide evidence to satisfy the security requirements of a Covered Entity prior to providing the BAA contract for signing 164.308(b)(1), 164.308(b)(3).

These features are following the recently released Vendor Management Solution (VMS) that integrates business associate agreements into a streamlined, automated contract management system.

Visit https://www.hipaaone.com to learn more about our software and solutions.

ABOUT HIPAA ONE

HIPAA One is a simple, automated and affordable HIPAA compliance software solution. The HIPAA One suite allows healthcare providers, payers and business associates of all sizes to focus on their important objectives: core competencies, improving compliance and reducing operating costs. Designed for auditors seeking advanced functionality, partners and office managers alike, the software scales from the single-doc practice to enterprise organizations needing to simplify complex problems, provide macro-analytics and “always current” HIPAA controls. To learn more about HIPAA One® visit http://www.hipaaone.com.

Share article on social media or email:

Stay Metrics to Provide Proprietary Data and Insight to TCA Profitability Program (TPP) Members


Stay Data promotional image featuring logos from TCA, TPP, and Stay Metrics

The TPP program is one of the best resources available to help carriers succeed. The data we provide is one more tool TPP carriers can use to know if they’re on the right track with retention. We’re looking forward to this great partnership.

The Truckload Carriers Association (TCA) Profitability Program (TPP) is pleased to announce that Stay Metrics, a provider of driver retention tools for motor carriers, has agreed to provide TPP members with proprietary data via the inGauge online benchmarking platform.

The data presented under the branding Stay Data™ banner, will be provided to TPP participants as part of the inGauge™ platform which is managed by FreightWaves®.

Stay Metrics will provide regular updates to the benchmarking data and highlight key insights that will be of interest to carriers seeking to remain competitive in the driver labor market.

The initial data set includes, among other exclusive data sets and charts, an updated Stay Days Table™ and insights into drivers’ perceptions on how easy it is to leave their carriers. Stay Metrics also provides several online resources to help participants develop strategies to improve and overcome the benchmarking numbers.

“The TPP program is one of the best resources available to help carriers succeed,” says Tim Hindes, co-founder and CEO of Stay Metrics. “The data we provide is one more tool TPP carriers can use to know if they’re on the right track with retention. We’re looking forward to this great partnership.”

Chris Henry, TPP Program Manager and FreightWaves’ VP of Carrier Profitability, adds, “TCA is committed to providing robust data and value to the TPP participants; thanks to Stay Metrics, this comes at no additional cost to the carrier member.”

Upon their next login to the inGauge platform, TPP participants will see the option for Stay Data™ in the main menu and can explore the data and supplementary resources.

Interested in sharing unique data that will be beneficial to the TPP participants? Contact Henry at chris(at)tcaingauge.com.

About Stay Metrics

Stay Metrics is a retention strategy firm. We’re passionate about partnering with transportation companies to help them increase driver retention and commitment. Our Stay Ahead platform amplifies your driver feedback. It encompasses our suite of driver lifecycle surveys and the Stay Metrics Reportal; which includes intervention opportunities, customizable reporting tools, and comparative industry data. In addition, our Driver Rewards platform gives carriers a custom-branded tool to sustain a driver-centric culture based on ongoing appreciation and engagement. The Stay Metrics’ team provides ongoing advice, insights, best-practice ideas, and industry-based research that supports our clients’ ongoing continuous improvement initiatives.

About TCA Profitability Program (TPP)

The TCA Profitability Program (TPP) is the trucking industry’s premier performance improvement solution, fusing TCA’s popular best practice groups and the powerful inGauge™ online benchmarking platform. TPP’s multi-tiered system allows carriers the flexibility to choose exactly how much time and resources they want to dedicate to the program, with plans ranging from simple snapshot composites to full online access and bi-annual meetings.

Share article on social media or email: